Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. Lunit and Microsoft are working ...

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

What’s impacting medical affairs today is the update to drug approvals: there’s more visibility, more scrutiny, and more ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into ...